Dual FDG and Octreotide PET/CT Imaging in a Patient With Malignant Pheochromocytoma and VHL Gene Mutation.
Dual FDG and octreotide PET/CT imaging may offer complementary insights into metastatic pheochromocytoma, aiding in treatment planning for VHL mutation cases.
Where it sits
this study against the rest of the octreotide corpusSummary and findings
A 59-year-old woman with malignant pheochromocytoma and a VHL gene mutation underwent dual FDG and octreotide PET/CT imaging. The imaging revealed intense uptake in various metastatic sites, aiding in prognostic stratification and therapeutic decision-making. Germline testing identified a VHL p.Asp126Asn mutation.
Abstract
A 59-year-old woman with a history of recurrent pheochromocytoma underwent 18 F-FDG and 18 F-octreotide PET/CT to evaluate metastatic disease following progression on targeted therapy. FDG PET/CT showed intense uptake in a mass in the right adrenal bed, bones, lung nodules, and lymph nodes. Octreotide PET/CT confirmed concordant high uptake in the corresponding lesions. Germline testing revealed a VHL p.Asp126Asn mutation. This "dual-tracer" strategy provided complementary information on glucose metabolism and somatostatin receptor expression, facilitating prognostic stratification and therapeutic decision-making in VHL-mutated pheochromocytoma.
Background
This study addresses the challenge of imaging metastatic pheochromocytoma, particularly in the context of VHL gene mutations. Previous research has shown that FDG PET/CT is effective in identifying metabolically active tumors, while octreotide PET/CT targets somatostatin receptors. Understanding the dual imaging approach is important for improving diagnostic accuracy and treatment planning in such cases.
Methods
The study involved a single patient, a 59-year-old woman with malignant pheochromocytoma and a VHL gene mutation. Dual imaging was performed using 18 F-FDG and 18 F-octreotide PET/CT. The primary outcome was the identification of metastatic lesions through imaging. No specific dose information or duration was reported.
Results
The FDG PET/CT scan showed intense uptake in the right adrenal bed, bones, lung nodules, and lymph nodes, indicating active metastatic disease. The octreotide PET/CT confirmed high uptake in the same lesions, suggesting the presence of somatostatin receptor expression. These findings provided complementary information for assessing the extent of the disease.
Interpretation
The dual-tracer imaging approach appears to provide a more comprehensive assessment of metastatic pheochromocytoma than either modality alone. However, as this is a single case report, the findings may not be broadly applicable. The study highlights the potential utility of combining metabolic and receptor-targeted imaging in complex cases, but further research is needed to confirm these benefits in larger populations.
Key findings
- 59-year-old woman with recurrent pheochromocytoma.
- 18 F-FDG PET/CT showed intense uptake in right adrenal bed, bones, lung nodules, and lymph nodes.
- 18 F-octreotide PET/CT confirmed concordant high uptake.
- Germline testing revealed VHL p.Asp126Asn mutation.
Limitations
- single case report
- no quantitative metrics reported
- limited generalizability
- descriptive findings only